<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02259439</url>
  </required_header>
  <id_info>
    <org_study_id>16022012</org_study_id>
    <nct_id>NCT02259439</nct_id>
  </id_info>
  <brief_title>Assessment of Updated Evaluation Scores in Critically ILL COPD Patients Admitted to Assiut University Hospital</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nermeen Aly Mahmoud Abdel Aleem</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) represent a leading&#xD;
      cause of morbidity and mortality.Patients admitted to hospital present higher mortality&#xD;
      rates.The investigators lack the specific tools that allow us to easily classify and&#xD;
      establish the individual prognosis for each patient during their hospitalization.&#xD;
&#xD;
      Rational of the study:to identify the predictive factors for hospital mortality in critically&#xD;
      ill patients admitted to hospital due to an episode of COPD exacerbation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Material and Methods:&#xD;
&#xD;
      A) sociodemographic variables:&#xD;
&#xD;
      Age, sex, marital status, occupation, pack\year.&#xD;
&#xD;
      B) clinical variables:&#xD;
&#xD;
      1- Dyspnea measured by the Medical Research Council (MRC) scale and the COPD Assessment Test&#xD;
      (CAT ) while stable, previous to admittance.&#xD;
&#xD;
      3- Charlson comorbidity index and age adjusted model.&#xD;
&#xD;
      4- The APACHE II scale: the severity of the episode upon admittance, calculated using the&#xD;
      APACHE II scale, using the worst value obtained in the first 24h after being admitted to&#xD;
      hospital.&#xD;
&#xD;
      5- the Sequential Organ Failure Assessment (SOFA) scale.&#xD;
&#xD;
      6- Lab parameters: such as glucose, albumin and heamatocrit&#xD;
&#xD;
      7- BAP-65 score: elevated blood urea nitrogen, altered mental status, pulse &gt; 109 beats/min,&#xD;
      age &gt; 65 years.&#xD;
&#xD;
      8- Assessment of symptom of gastroesophageal reflux disease.&#xD;
&#xD;
      9-Glasgow scale score.&#xD;
&#xD;
      10-CURB 65 :&quot;C&quot; stands for &quot;confused&quot;; &quot;U&quot; stands for BUN greater than19 mg/dL; &quot;R&quot; stands&#xD;
      for &quot;respiration more than 30 breaths per minute&quot;&quot;B&quot; stands for blood pressure less than 90&#xD;
      mm Hg systolic or diastolic blood pressure 60 mm Hg or less; &quot;65&quot; stands â‰¥65 years.&#xD;
&#xD;
      11-CAUDA 70: C: Confusion, Acidosis (pH &lt;7.35), Urea &gt;7mmol/L, MRC Dyspnoea score &gt;4, Albumin&#xD;
      &lt;35g/L, Age &gt;70 years. One point was assigned to each variable present, giving a six point&#xD;
      scoring system.&#xD;
&#xD;
      12-The COPD and Asthma Physiology Score.&#xD;
&#xD;
      13-The early warning score.&#xD;
&#xD;
      14-ADO index: comprised of age, dyspnea by the MRC, and FEV1. Scores ranged from 0 (best&#xD;
      status) to 5 (worst status) for age, 0-3 for MRC, and 0-2 for FEV1. Points for each component&#xD;
      were added so that the ADO index ranged from 0 to 10.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Calculate the mortality of exacerbated patients based on APACHE II and SOFA score, respiratory rate upon admittance, age, pO2/ FiO2 in the first few hours of admittance.</measure>
    <time_frame>24 hours</time_frame>
    <description>Calculate mortality caused by AECOPD depend upon APACHE II and SOFA score</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        We include for study all patients critically ill hospitalized for COPD exacerbation during&#xD;
        the study period.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  We include for study all patients critically ill hospitalized for COPD exacerbation&#xD;
             during the study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refuse to be admitted to hospital after having been properly informed,&#xD;
             and their families as well, of the possible risks that they are assuming.&#xD;
&#xD;
          -  Specific diagnosis: pulmonary edema, rib fractures, aspiration, pleural effusion, etc.&#xD;
             upon admission.&#xD;
&#xD;
          -  Other associated respiratory pathology that determines treatment: pulmonary fibrosis,&#xD;
             kyphoscoliosis, neuromuscular pathology, upper airway obstruction, extensive&#xD;
             tuberculosis sequelae.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nermeen Abdel Aleem</last_name>
    <phone>01007174772</phone>
    <email>nermeenabdelaleem@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed Metwally</last_name>
    <phone>01223971614</phone>
    <email>melhadi@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chest Department-faculty of medicine-Assuit university</name>
      <address>
        <city>Assuit</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>September 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2014</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Nermeen Aly Mahmoud Abdel Aleem</investigator_full_name>
    <investigator_title>chest department- faculity of medicine -Assiut university- Egypt</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

